Clareo Health | An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
With
Ono Pharmaceutical Co., Ltd.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 1
Histologically confirmed Stage IV, or Recurrent NSCLC with no prior systemic anticancer therapy
Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per response evaluation criteria in solid tumors version (RECIST) 1.1 criteria
PD-L1+ on immunohistochemistry testing performed by central lab
Men and women, ages ≥ 18 years of age
You may not be if
Known epidermal growth factor receptor (EGFR) mutations which are sensitive to available targeted inhibitor therapy
Known anaplastic lymphoma kinase (ALK) translocations
